Improving medical communication in preventive medicine and health screening.
Health screening plays an important role in preventive medicine in Japan. Many healthcare institutions provide comprehensive health screening programs that include laboratory tests, imaging examinations, and lifestyle assessment.
In recent years, the number of international patients receiving health screening in Japan has increased. As a result, the need for clear and natural medical English communication has become increasingly important.
However, many medical reports are still translated directly from Japanese, which can lead to unnatural expressions or misunderstandings. Accurate and well-structured medical English is essential for effective communication with international patients and overseas physicians.
Hama Health focuses on improving medical communication in health screening through the development of standardized English medical comments and reporting templates.
Our work supports physicians and healthcare institutions by providing guidance on medical English writing, clinical documentation, and communication for international patients.
By improving the clarity and quality of medical reports, healthcare providers can deliver more effective preventive care and strengthen international medical collaboration.
Hama Health develops practical medical English resources for health screening and international medical communication in Japan.
Japan has a well-established system of health screening that plays an important role in preventive medicine. Comprehensive screening programs often include laboratory testing, imaging studies, and lifestyle assessments designed to detect early signs of disease.
With the increasing number of international residents and visitors in Japan, healthcare providers are encountering more patients who require medical explanations in English.
Effective communication is essential not only for explaining test results but also for providing reassurance and appropriate follow-up recommendations.
However, health screening reports are frequently translated directly from Japanese, which can result in expressions that are difficult for international patients to understand.
Clear and structured medical English helps physicians explain findings more effectively and ensures that patients receive accurate information about their health status.
Standardized medical English expressions and reporting templates can improve consistency, reduce misunderstandings, and support better communication between physicians and patients.
Hama Health supports healthcare institutions by providing guidance on medical English reporting, health screening communication, and international patient support in Japan.
This initiative is part of the Hama Health Medical English Project for improving clinical communication in preventive medicine.
Developing practical medical English resources for health screening in Japan.
Clear and accurate medical communication is essential in modern healthcare, especially when caring for international patients.
In Japan, health screening plays a central role in preventive medicine. However, medical explanations and reports are often translated directly from Japanese, which may lead to expressions that are difficult for international patients to understand.
The Hama Health Medical English Project aims to improve medical communication in health screening by developing practical medical English resources.
The project focuses on creating standardized English templates for health screening reports, clinical explanations, and follow-up recommendations.
These resources are designed to support physicians, healthcare institutions, and medical staff in communicating clearly with international patients.
Areas of development include:
Medical English comment templates for health screening
Standardized explanations for common clinical findings
English reporting templates for preventive medicine
Communication support for international patients
Through this initiative, Hama Health seeks to contribute to better medical communication and international collaboration in healthcare.
人間ドック不要論への反論 — エビデンスにもとづく再評価
Re-examining the case for comprehensive health screening in Japan in light of modern evidence.
Introduction
Ningen Dock（人間ドック）— Japan's tradition of comprehensive health screening — has played a central role in preventive medicine for over six decades. It combines laboratory testing, imaging studies, physical examination, and lifestyle assessment in a single, structured visit, with the goal of detecting disease at a stage when intervention is most effective.
In recent years, however, a growing voice — including online medical commentators with substantial audiences — has questioned whether comprehensive health screening is worthwhile at all. The argument is almost invariably traced to a single source: a Cochrane systematic review by Krogsbøll and colleagues, first published in 2012 and updated in 2019, which concluded that "general health checks" did not significantly reduce overall mortality or cardiovascular mortality. From this single conclusion, "the human dock is unnecessary"（「人間ドック不要論」）has been repeated in lay media, in social media, and in popular YouTube content reaching hundreds of thousands of viewers.
What is rarely mentioned — by either critics or, often, by the medical professionals who echo their claims — is what the Cochrane review actually evaluated.
This article offers an evidence-based response to that skepticism. It examines the actual content of the trials included in the Cochrane review, demonstrates the substantial gap between those interventions and modern Japanese Ningen Dock, and explains why a structured, evolving model of health screening — rather than its abandonment — best serves preventive medicine in Japan.
What the Cochrane Review Actually Studied
The 2019 Cochrane update included 17 randomized trials with approximately 251,000 participants. Repeated as a headline statistic, this sounds definitive. But a direct reading of the Cochrane review's Characteristics of Included Studies table reveals something quite different.
The included trials were conducted between 1963 and 1999. Six of the seventeen trials began in the 1960s. Not a single included trial began after the year 2000.
The interventions evaluated in these trials — taken directly from the Cochrane review's own documentation — consisted primarily of:
Göteborg 1963 (Sweden): Blood pressure, ECG, urinalysis, basic blood chemistry, chest X-ray, general examination
Kaiser Permanente 1965 (USA): Blood pressure, ECG, chest X-ray, mammography, vision/hearing, basic blood panel
South-East London 1967 (UK): Brief examination, height/weight, vision/hearing, chest X-ray, ECG, basic chemistry, fecal occult blood
Malmö 1969 (Sweden): Blood pressure, cholesterol, ECG, chest X-ray, lung function
WHO 1971 (multinational): Blood pressure, total cholesterol, weight, smoking questionnaire
Salt Lake City 1972 (USA): Multiphasic check with chest X-ray, ECG, basic blood tests, mammography, cervical cytology
OXCHECK 1989 (UK): Blood pressure, total cholesterol, height/weight, lifestyle questionnaire (nurse-led)
Family Heart 1990 (UK): BMI, blood pressure, total cholesterol, random glucose, Dundee risk score
Ebeltoft 1992 (Denmark): ECG, total cholesterol, blood pressure, lung function, basic chemistry, urine dipstick
Inter99 1999 (Denmark): Blood pressure, fasting lipids, oral glucose tolerance test, lung function, PRECARD risk assessment
This is the totality — or close to it — of what the Cochrane review actually measured.
Now consider the modern Japanese Ningen Dock examination. A standard comprehensive program typically includes diagnostic modalities that fall into three clear categories when compared to the Cochrane review's evidence base:
✅ Modalities included in some Cochrane trials:
Blood pressure measurement (in 15 of 17 included trials)
Total cholesterol (in most trials, though using 1960s–1990s methodology)
Basic blood chemistry (in some trials)
Chest X-ray (in 5 older trials, all before 1973)
⚠️ Modalities included in only 1–3 old trials:
Abdominal ultrasound — only one trial (DanMONICA 1982)
Mammography — three trials, all using film-era equipment
Cervical cytology — three trials, using pre-modern protocols
Fecal occult blood — one trial (South-East London 1967), using guaiac-based methods rather than modern FIT
❌ Modalities NOT included in ANY Cochrane trial:
HbA1c-based diabetes diagnosis
Upper gastrointestinal endoscopy (gastric cancer screening)
Lower GI endoscopy or modern fecal immunochemical testing
Low-dose CT for lung cancer screening
MRI of any organ
FIB-4 for liver fibrosis stratification
Bone mineral density measurement (DXA)
Helicobacter pylori serology
Hepatitis B / C virus screening
Multi-component cardiovascular risk scores (JSH2025, Hisayama)
Modern lipid stratification (LDL subclasses, non-HDL cholesterol)
Carotid intima-media thickness measurement
Echocardiography
The diagnostic modalities that define a modern Japanese Ningen Dock — gastrointestinal endoscopy, abdominal ultrasound, low-dose CT, FIB-4, modern cancer screening, contemporary risk stratification — were almost entirely absent from the trials the Cochrane review evaluated.
To cite this review as evidence that "Ningen Dock is unnecessary" is, quite simply, a category error. It is the equivalent of citing a 1965 study on simple aspirin trials as evidence that modern interventional cardiology is ineffective. The interventions evaluated bear only superficial resemblance to what is actually delivered in a modern comprehensive Japanese health screening program.
This is not a subtle methodological point. The Cochrane review's authors themselves explicitly acknowledged that "most trials were old" and that thresholds for treatment, risk assessment methods, and available preventive interventions have changed substantially since. Yet this caveat is rarely mentioned by those who cite the review's headline conclusion.
A Note on Responsible Citation of Evidence
It is one thing for a lay reader to repeat a misleading summary of a complex systematic review. It is another for medical professionals — including those with substantial public platforms — to do the same. The responsibility of evidence-based medicine includes reading beyond the abstract: asking what trials were included, when they were conducted, what they actually measured, and whether the conclusions can reasonably be extended to interventions that bear little resemblance to what was studied.
The Cochrane Collaboration itself has formally clarified this. The Cochrane Handbook for Systematic Reviews of Interventions explicitly states that a Cochrane review is one source of evidence rather than a final verdict, and that its conclusions must be interpreted alongside guideline recommendations, real-world data, and the clinical context in which screening is delivered.
A 2022 systematic review by Schmidt and colleagues further documented that the majority of medical interventions evaluated in recent Cochrane reviews are not supported by high-quality evidence — meaning that "Cochrane found no benefit" frequently reflects evidence gaps rather than proven absence of benefit. The distinction is critical: absence of evidence is not evidence of absence.
Modern guideline bodies — including the National Institute for Health and Care Excellence (NICE) in the United Kingdom, the US Preventive Services Task Force, the World Health Organization, and the Japanese Minds guideline library — continue to incorporate Cochrane reviews as one important source among many. None treats them as a stand-alone basis for discontinuing established screening programs.
The Japanese Evidence: A Different Picture
When the question is reframed from "do brief primary-care risk factor checks from the 1960s–1990s reduce all-cause mortality?" to "does comprehensive screening, as practiced in modern Japan, improve outcomes for the population it serves?", the evidence becomes considerably more favorable — and the Cochrane review, on this reframed question, simply does not apply.
Japanese population data show that organized cancer screening programs have contributed to declining mortality from gastric, colorectal, and cervical cancers over recent decades. Cardiovascular risk identification through hypertension, lipid, and glucose screening — followed by lifestyle counseling and, where appropriate, pharmacological treatment — is one of the most cost-effective interventions in medicine, with consistent international evidence supporting blood pressure control, statin therapy in selected populations, and glycemic management.
Modern Ningen Dock（人間ドック）has evolved continuously. Contemporary programs incorporate the Hisayama cardiovascular risk score, the JSH2025 hypertension framework, the JDS 2024 diabetes diagnostic criteria, the JAS 2022 atherosclerosis guideline, FIB-4 for liver fibrosis stratification, low-dose CT for lung cancer screening in high-risk smokers (per NLST and NELSON evidence showing 20–24% mortality reduction), and upper GI endoscopy for early gastric cancer detection. None of these modalities was evaluated in any of the trials included in the Cochrane review.
Addressing the Common Criticisms
Overdiagnosis. This is a real phenomenon and deserves serious attention. The well-known example of thyroid cancer screening in South Korea — where intensive ultrasound screening led to a large rise in incidence without a corresponding fall in mortality — is frequently cited as a warning. The response, however, is not to abandon screening but to design it intelligently. Active surveillance protocols, evidence-based thresholds for intervention, and careful patient communication can mitigate overdiagnosis without sacrificing early detection. The net benefit — not the absence of any harm — should be the criterion for evaluating screening.
Lead-time and length bias. These statistical phenomena can make screening appear to extend life when it merely shifts the moment of diagnosis. They are real considerations in trial design but do not affect the underlying biology: detecting and treating a cancer at stage I rather than stage IV materially changes the patient's prognosis. Randomized trials with mortality endpoints — including the NLST and NELSON trials for lung cancer screening — control for these biases. These are precisely the modern trials, evaluating precisely the modern modalities, that were not included in the Cochrane review on general health checks.
Cost-effectiveness. Critics sometimes argue that screening costs outweigh benefits. In the Japanese context, where Ningen Dock（人間ドック）is largely funded through employer health insurance and personal payment, the cost structure differs fundamentally from the public-health-funded mass screening programs evaluated in many international studies. Moreover, the early identification of hypertension, diabetes, and dyslipidemia — conditions that, untreated, lead to expensive late-stage cardiovascular and renal complications — generates downstream savings that are rarely captured in screening-only cost analyses.
The Path Forward: Evolve, Not Abandon
The honest answer to "is general health screening effective?" is that it depends on what is screened, how, in whom, and with what follow-up. A poorly designed screening program can produce more harm than benefit. A well-designed one — with evidence-based thresholds, integrated cardiovascular risk assessment, structured referral pathways, and clear patient communication — is among the most impactful tools in preventive medicine.
The future of Ningen Dock（人間ドック）lies not in retreat but in continuous refinement: incorporating updated guidelines as they emerge, removing tests that no longer meet evidence standards, integrating new modalities such as low-dose CT for high-risk smokers and FIB-4 for liver disease stratification, and — critically — communicating findings clearly so that patients can act on them.
This last point is where medical communication intersects with clinical evidence. A screening finding has value only when the patient understands what it means and what to do next. For international patients in Japan, this requires not only accurate clinical assessment but also clear, well-structured medical English — an area where standardized reporting templates and consistent terminology make a measurable difference.
Conclusion
Ningen Dock（人間ドック）is not above critique. Programs must be regularly re-examined against current evidence, tests that no longer meet contemporary standards should be retired, and individual screening modalities should each be judged on their own evidence base. The legitimate questions raised by overdiagnosis research, by individual-test effectiveness studies, and by health-economics analyses all deserve serious engagement.
But the broader argument that comprehensive health screening is fundamentally unnecessary rests on a citation chain that, when traced to its source, dissolves. The Cochrane review on general health checks evaluated trials beginning between 1963 and 1999, primarily measuring blood pressure, cholesterol, and basic risk factors in primary-care settings. It did not evaluate gastrointestinal endoscopy. It did not evaluate abdominal ultrasound. It did not evaluate low-dose CT. It did not evaluate HbA1c-based diabetes diagnosis. It did not evaluate FIB-4. It did not evaluate any of the modalities that define a modern Japanese Ningen Dock.
To repeat the review's headline conclusion as evidence against modern comprehensive screening — without acknowledging what was actually studied — is not evidence-based medicine. It is the appearance of evidence-based medicine, used to support a conclusion the evidence does not establish.
Comprehensive health screening, properly designed and clearly communicated, remains one of the most valuable contributions modern medicine can make to long-term population health. At Hama Health, we believe this value is worth defending — and worth communicating, in clear medical English, to the international patients and physicians who increasingly form part of the Japanese healthcare landscape.
This article is part of the Hama Health Medical English Project, which develops practical resources for medical communication in preventive medicine and health screening in Japan.
A comprehensive Japanese-language treatise on this topic — 「人間ドック不要論への反論 — エビデンスにもとづく再評価」 (46 pages, 49 references) — is available for colleagues who wish to read the full evidence review, including a detailed examination of each of the 17 trials included in the Cochrane review. Please contact Hama Health for access.